Cosmin Andrei Cismaru

Institution"Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca
AddressRomania
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 11 Covid-19 publications, with a maximum of 3 publications in April 2020
    All Publications
    Bar chart showing 11 publications over 2 distinct years, with a maximum of 10 publications in 2020
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Nabavi SF, Habtemariam S, Berindan-Neagoe I, Cismaru CA, Schaafsma D, Ghavami S, Banach M, Aghaabdollahian S, Nabavi SM. Rationale for Effective Prophylaxis Against COVID-19 Through Simultaneous Blockade of Both Endosomal and Non-Endosomal SARS-CoV-2 Entry into Host Cell. Clin Transl Sci. 2021 03; 14(2):431-433. PMID: 33406317.
      Citations: 4     Fields:    Translation:HumansCells
    2. Cismaru CA, Cismaru GL, Nabavi SF, Ghanei M, Burz CC, Nabavi SM, Berindan Neagoe I. Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19. J Cell Mol Med. 2021 01; 25(1):591-595. PMID: 33211389.
      Citations: 1     Fields:    Translation:HumansCells
    3. Cismaru CA, Cismaru GL, Seyed Nabavi F, Seyed Nabavi M, Berindan-Neagoe I. COVID-19 and antimalarials. Have we been doing it wrong all along? Eur J Pharmacol. 2021 Jan 15; 891:173694. PMID: 33130275.
      Citations:    Fields:    Translation:Humans
    4. Nabavi SF, Habtemariam S, Sureda A, Banach M, Berindan-Neagoe I, Cismaru CA, Bagheri M, Bagheri MS, Nabavi SM. Glucose-6-phosphate dehydrogenase deficiency and SARS-CoV-2 mortality: Is there a link and what should we do? Clin Biochem. 2020 Dec; 86:31-33. PMID: 32950470.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
    5. Dowran R, Nabavi SF, Habtemariam S, Banach M, Shahmohamadnejad S, Cismaru CA, Berindan-Neagoe I, Sahebnasagh A, Nabavi SM. Various interferon (IFN)-inducible transmembrane (IFITM) proteins for COVID-19, is there a role for the combination of mycophenolic acid and interferon? Biochimie. 2020 Oct; 177:50-52. PMID: 32805303.
      Citations: 1     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    6. Habtemariam S, Berindan-Neagoe I, Cismaru CA, Schaafsma D, Nabavi SF, Ghavami S, Banach M, Nabavi SM. Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID-19: Shoot the messenger! J Cell Mol Med. 2020 09; 24(17):10267-10269. PMID: 32677763.
      Citations: 2     Fields:    Translation:HumansAnimals
    7. Sureda A, Alizadeh J, Nabavi SF, Berindan-Neagoe I, Cismaru CA, Jeandet P, Los MJ, Clementi E, Nabavi SM, Ghavami S. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management? Eur J Pharmacol. 2020 Sep 05; 882:173288. PMID: 32561291.
      Citations: 25     Fields:    Translation:HumansCellsPHPublic Health
    8. Habtemariam S, Nabavi SF, Ghavami S, Cismaru CA, Berindan-Neagoe I, Nabavi SM. Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2. Pharmacol Res. 2020 07; 157:104853. PMID: 32360584.
      Citations: 12     Fields:    Translation:HumansCellsPHPublic Health
    9. Habtemariam S, Nabavi SF, Berindan-Neagoe I, Cismaru CA, Izadi M, Sureda A, Nabavi SM. Should we try the antiinflammatory natural product, celastrol, for COVID-19? Phytother Res. 2020 06; 34(6):1189-1190. PMID: 32347602.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
    10. Nabavi SF, Habtemariam S, Clementi E, Berindan-Neagoe I, Cismaru CA, Rasekhian M, Banach M, Izadi M, Bagheri M, Bagheri MS, Nabavi SM. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2. Arch Med Sci. 2020; 16(3):519-521. PMID: 32399097.
      Citations: 7     
    11. Sarkar K, Sil PC, Nabavi SF, Berindan-Neagoe I, Cismaru CA, Nabavi SM, Habtemariam S. Possible Targets and Therapies of SARS-CoV-2 Infection. Mini Rev Med Chem. 2020; 20(18):1900-1907. PMID: 32767936.
      Citations: 1     Fields:    Translation:Humans
    Cismaru's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (60)
    Explore
    _
    Co-Authors (27)
    Explore
    _
    Similar People (60)
    Explore
    _